Intercept Pharmaceuticals Stock Beta
Intercept Pharmaceuticals fundamentals help investors to digest information that contributes to Intercept Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Intercept Stock. The fundamental analysis module provides a way to measure Intercept Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intercept Pharmaceuticals stock.
Intercept |
Intercept Pharmaceuticals Company Beta Analysis
Intercept Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Intercept Pharmaceuticals Beta | 0.88 |
Most of Intercept Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intercept Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Intercept Pharmaceuticals has a Beta of 0.884. This is 2.79% higher than that of the Biotechnology sector and 36.4% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Intercept Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intercept Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intercept Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Intercept Pharmaceuticals by comparing valuation metrics of similar companies.Intercept Pharmaceuticals is currently under evaluation in beta category among its peers.
Intercept Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Intercept Pharmaceuticals is expected to follow.
Intercept Fundamentals
Return On Equity | -0.64 | |||
Return On Asset | -0.0723 | |||
Profit Margin | (0.19) % | |||
Operating Margin | 0.02 % | |||
Current Valuation | 695.84 M | |||
Shares Outstanding | 41.81 M | |||
Shares Owned By Insiders | 3.12 % | |||
Shares Owned By Institutions | 81.30 % | |||
Number Of Shares Shorted | 10.19 M | |||
Price To Earning | (3.88) X | |||
Price To Book | 44.19 X | |||
Price To Sales | 1.60 X | |||
Revenue | 285.71 M | |||
Gross Profit | 284.73 M | |||
EBITDA | (61.7 M) | |||
Net Income | (174.86 M) | |||
Cash And Equivalents | 404.78 M | |||
Cash Per Share | 13.58 X | |||
Total Debt | 332.67 M | |||
Debt To Equity | 411.20 % | |||
Current Ratio | 3.22 X | |||
Book Value Per Share | 1.72 X | |||
Cash Flow From Operations | (26.78 M) | |||
Short Ratio | 2.64 X | |||
Earnings Per Share | (4.26) X | |||
Price To Earnings To Growth | (0.69) X | |||
Target Price | 19.0 | |||
Number Of Employees | 341 | |||
Beta | 0.88 | |||
Market Capitalization | 794.36 M | |||
Total Asset | 553.71 M | |||
Retained Earnings | (2.14 B) | |||
Working Capital | 310.05 M | |||
Current Asset | 641.69 M | |||
Current Liabilities | 47.37 M | |||
Z Score | -3.15 | |||
Net Asset | 553.71 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world |